Therapeutic Advances in Medical Oncology · 13 authors, 16 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective cohort study evaluated the LV5FU2-carboplatin combination in 91 patients with advanced pancreatic cancer after prior treatment failure. The treatment showed limited overall efficacy, with a median progression-free survival of 2.7 months and median overall survival of 4.2 months.
This retrospective single-center cohort study analyzed 91 patients with advanced pancreatic ductal adenocarcinoma (PDAC) who received LV5FU2-carboplatin chemotherapy after failing standard regimens. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Results showed a median PFS of 2.7 months and a median OS of 4.2 months. Multivariable analysis identified several factors associated with longer PFS, including fewer prior treatment lines, a full dose of carboplatin, and initiation of treatment more than 18 months after diagnosis. The treatment had acceptable tolerance, though neutropenia (24.7%) and thrombocytopenia (11.8%) were the most common grade 3–4 adverse events. The study's main limitations are its retrospective design, lack of a control group, and potential selection bias toward patients with better prognosis.
